arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

PRECISION BIOSCIENCES INC

DTIL
$9.85 ▲ +1.78 (+22.06%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
9 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

PRECISION BIOSCIENCES INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $126.3M
Dividend Yield —
Revenue Growth -50.1% ↘
Op. Margin -152.2% ↘
ROIC -44.7% ↘
FCF / Share $-5.13 ↗
Trailing P/E —
Price / Book 2.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$34.26M
↓ -50.1% —
Net Income Profit after all expenses
$-45.72M
↓ -738.0% —
Operating Margin Operating profit as % of sales
-152.2%
↓ -299.6% 0th
FCF / Share Free cash flow per share
$-5.13
↑ +40.0% —
Long-Term Debt Long-term obligations
$22.22M
↑ +796.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns ↑
15
Financial Health ↑
20
Cash Quality ↑
78

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 39 quarters